BAGSVAERD, DENMARK--(Marketwire - June 13, 2008) - At Novo Nordisk’s ordinary general meeting on 12 March 2008 it was decided to reduce the company’s B share capital from DKK 539,472,800 to DKK 526,512,800 by cancellation of part of the company’s portfolio of own B shares at a nominal value of DKK 12,960,000 divided into 12,960,000 B shares of DKK 1.
